Lilly Eyes Quick FDA Approval For Orforglipron In Obesity, While Novo Submits CagriSema

Phase III Data Support Oral Drug As Maintenance

 
• By Joseph Haas
  
Lilly expects quick turnaround on its FDA filing of orforglipron • Source: Shutterstock

More from Strategy

More from Business